Sadly, more than 10 children are diagnosed with cancer in the UK every day, with one of the most common childhood cancers being neuroblastoma; a childhood cancer that originates from developing nerve cells.
For children with advanced-stage neuroblastoma, prognosis using traditional treatments is poor, with only 30—40% surviving in the long-term. However, our ground-breaking immunotherapy trials are giving new hope to these children and their families. Dr Juliet Gray, Associate Professor in Paediatric Oncology at the University, is leading new UK immunotherapy studies, looking at improving neuroblastoma treatments and their effectiveness.
Click here to read the inspiring interview with Dr. Juliet Gray.
